Patents by Inventor William E. Bauta

William E. Bauta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190275027
    Abstract: Bis-benzyl-tetrahydroisoquinoline analogs that are derivatives of the cyclic products tetrandrine (TETN) and cepharanthine (CEPH). The analogs indicate activity against filovirus infections, including the type species Marburg virus (MARV) and Ebola virus (EBOV).
    Type: Application
    Filed: March 9, 2018
    Publication date: September 12, 2019
    Inventors: William E. BAUTA, Jonathan A. BOHMANN, Michael W. TIDWELL, Andrey D. MALAKHOV, Alejandro SANTILLAN, JR.
  • Patent number: 10377721
    Abstract: Provided herein is a process and intermediates for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, using cyanamide in the reaction.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: August 13, 2019
    Assignee: Lumos Pharma, Inc.
    Inventors: William R. Cantrell, Jr., William E. Bauta
  • Publication number: 20190184021
    Abstract: A porphyrin compound and composition made therefrom comprising a therapeutically effective dose of a porphyrin bound via a linker to an anti-cancer agent useful in treating cancer in a patient in need thereof or to treat cancer cells in-vitro. The compounds and compositions may be delivered by a drug delivery device as disclosed here and be part of a kit.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 20, 2019
    Inventors: Maria Zannes, Vivienne I. Rebel, William E. Bauta
  • Publication number: 20180354910
    Abstract: Provided herein is a process and intermediates for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, using cyanamide in the reaction.
    Type: Application
    Filed: August 21, 2018
    Publication date: December 13, 2018
    Inventors: William R. Cantrell, JR., William E. Bauta
  • Publication number: 20180303823
    Abstract: The present disclosure relates to the preparation of polymorphic mixtures of Cepharanthine.2HCl. Mixtures of at least two polymorphic forms can be formed into a mobile liquid phase in organic/aqueous solvent mixtures along with enteric polymer that can be spray dried to produce solid particulate enteric formulations for medicinal drug-treatment applications.
    Type: Application
    Filed: March 19, 2018
    Publication date: October 25, 2018
    Inventors: William E. BAUTA, Joseph A. McDONOUGH, Hong DIXON, Steven T. WELLINGHOFF, Kevin FITZPATRICK
  • Patent number: 10081605
    Abstract: Provided herein is a process and intermediates for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, using cyanamide in the reaction.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: September 25, 2018
    Assignee: Lumos Pharma, Inc.
    Inventors: William R. Cantrell, Jr., William E. Bauta
  • Publication number: 20180044299
    Abstract: Provided herein is a process an intermediates for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, using cyanamide in the reaction.
    Type: Application
    Filed: March 11, 2016
    Publication date: February 15, 2018
    Inventors: William R. Cantrell, JR., William E. Bauta
  • Publication number: 20170273950
    Abstract: Provided herein is a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, using cynamide in the reaction.
    Type: Application
    Filed: September 1, 2015
    Publication date: September 28, 2017
    Applicant: Lumos Pharma, Inc.
    Inventors: William R. Cantrell, JR., William E. Bauta
  • Publication number: 20160280716
    Abstract: The present disclosure relates to the preparation of pharmaceutically acceptable salt forms of the medicinal alkaloids Cepharanthine and Tetrandrine with improved solubility and physicochemical properties compared with the free base form of these alkaloids.
    Type: Application
    Filed: March 23, 2016
    Publication date: September 29, 2016
    Inventors: William E. BAUTA, Joseph A. McDonough, Mathew P.D. MAHINDARATNE, Robert A. DAVEY
  • Patent number: 9162983
    Abstract: The present invention relates to organophosphate-inhibited acetylcholinesterase (AChE) reactivators with central nervous system (CNS) bioavailability and their associated methods of preparation including their use for treatment of exposure to AChE inhibitors such as an organophosphate (OP) insecticides and nerve agents.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: October 20, 2015
    Assignee: SOUTHWEST RESEARCH INSTITUTE
    Inventors: William E. Bauta, William R. Cantrell, Jr., Michael W. Tidwell
  • Publication number: 20140350262
    Abstract: The present invention relates to organophosphate-inhibited acetylcholinesterase (AChE) reactivators with central nervous system (CNS) bioavailability and their associated methods of preparation including their use for treatment of exposure to AChE inhibitors such as an organophosphate (OP) insecticides and nerve agents.
    Type: Application
    Filed: May 22, 2014
    Publication date: November 27, 2014
    Applicant: Southwest Research Institute
    Inventors: William E. BAUTA, William R. CANTRELL, JR., Michael W. TIDWELL
  • Publication number: 20130035306
    Abstract: The present invention provides for the preparation ?-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy-?-D-adenine nucleosides wherein a blocked 2-deoxy-?-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative. The forgoing aspects of the present invention are utilized in the preparation of a clofarabine composition wherein the ratio of ? to ?-anomer is at least 99:1.
    Type: Application
    Filed: July 6, 2012
    Publication date: February 7, 2013
    Applicant: Genzyme Corporation
    Inventors: William E. Bauta, Brian D. Burke, Brian E. Schulmeier, William R. Cantrell, JR., Dennis P. Lovett, Jose Puente
  • Publication number: 20110282045
    Abstract: The present invention for the stereoselective preparation of 2-deoxy-?-D-adenine nucleosides wherein a blocked 2-deoxy-?-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative.
    Type: Application
    Filed: May 13, 2011
    Publication date: November 17, 2011
    Inventors: William E. Bauta, Brian D. Burke, Brian E. Schulmeier, William R. Cantrell, JR., Dennis P. Lovett, Jose Puente
  • Patent number: 7947824
    Abstract: The present invention for the stereoselective preparation of 2-deoxy-?-D-adenine nucleosides wherein a blocked 2-deoxy-?-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative.
    Type: Grant
    Filed: May 4, 2009
    Date of Patent: May 24, 2011
    Assignee: Genzyme Corporation
    Inventors: William E. Bauta, Brian D. Burke, Brian E. Schulmeier, William R. Cantrell, Jr., Dennis P. Lovett, Jose Puente
  • Publication number: 20090286971
    Abstract: The present invention for the stereoselective preparation of 2-deoxy-?-D-adenine nucleosides wherein a blocked 2-deoxy-?-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative.
    Type: Application
    Filed: May 4, 2009
    Publication date: November 19, 2009
    Inventors: William E. Bauta, Brian D. Burke, Brian E. Schulmeier, William R. Cantrell, JR., Dennis P. Lovett, Jose Puente
  • Patent number: 7528247
    Abstract: The present invention for the stereoselective preparation of 2-deoxy-?-D-adenine nucleosides wherein a blocked 2-deoxy-?-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative.
    Type: Grant
    Filed: January 9, 2004
    Date of Patent: May 5, 2009
    Assignee: Genzyme Corporation
    Inventors: William E. Bauta, Brian D. Burke, Brian E. Schulmeier, William R. Cantrell, Jr., Dennis P. Lovett, Jose Puente
  • Patent number: 7419965
    Abstract: The subject of the present invention is specific lipidesters of halogenated nucleotides of the following formula wherein R1, R2, R3, X and Y are defined as described herein and salts thereof, said compounds have anti-cancer properties; pharmaceutical compositions containing the compounds, a method of synthesizing the compounds, and a method of using the compounds for treating malignant tumors.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: September 2, 2008
    Assignee: Heidelberg Pharma AG
    Inventors: Dieter Herrmann, Brigitte Heckl-Oestreicher, Christoph Mueller, Christian Lutz, Robert Voigt, William E. Bauta
  • Patent number: 6797838
    Abstract: The present invention provides a process for the preparation of homophthlate esters useful in the preparation of homophthalic anhydride reactants.
    Type: Grant
    Filed: July 28, 2003
    Date of Patent: September 28, 2004
    Assignee: Ilex Products, Inc.
    Inventors: William E. Bauta, William R. Cantrell, Jr., Dennis P. Lovett
  • Publication number: 20040024240
    Abstract: The present invention provides a process for the preparation of homophthlate esters useful in the preparation of homophthalic anhydride reactants.
    Type: Application
    Filed: July 28, 2003
    Publication date: February 5, 2004
    Inventors: William E. Bauta, William R. Cantrell, Dennis P. Lovett
  • Patent number: 6680382
    Abstract: The present invention provides for the preparation &bgr;-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of a base and solvent. The present invention also provides for the stereoselective preparation of 2-deoxy-&bgr;-D-adenine nucleosides wherein a blocked 2-deoxy-&agr;-D-arabinofuranosyl halide is coupled with the salt of an adenine derivative. The forgoing aspects of the present invention are utilized in the preparation of a clofarabine composition wherein the ratio of &bgr; to &agr;-anomer is at least 99:1.
    Type: Grant
    Filed: August 1, 2002
    Date of Patent: January 20, 2004
    Assignee: Ilex Products, Inc.
    Inventors: William E. Bauta, Brian D. Burke, Brian E. Schulmeier, William R. Cantrell, Jr., Dennis P. Lovett, Jose Puente